Evoke Pharma Inc
NASDAQ:EVOK

Watchlist Manager
Evoke Pharma Inc Logo
Evoke Pharma Inc
NASDAQ:EVOK
Watchlist
Price: 22.15 USD -0.23% Market Closed
Market Cap: 18.9m USD

Net Margin
Evoke Pharma Inc

-36.2%
Current
-154%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-36.2%
=
Net Income
-5.2m
/
Revenue
14.4m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Evoke Pharma Inc
NASDAQ:EVOK
18.9m USD
-36%
US
Eli Lilly and Co
NYSE:LLY
1T USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
498.9B USD
27%
CH
Roche Holding AG
SIX:ROG
259.1B CHF
15%
UK
AstraZeneca PLC
LSE:AZN
208.8B GBP
16%
US
Merck & Co Inc
NYSE:MRK
264.8B USD
30%
CH
Novartis AG
SIX:NOVN
207.2B CHF
26%
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK
33%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
-126%
US
Pfizer Inc
NYSE:PFE
143.2B USD
16%
No Stocks Found

Evoke Pharma Inc
Glance View

Market Cap
18.9m USD
Industry
Pharmaceuticals

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. The company is headquartered in Solana Beach, California and currently employs 4 full-time employees. The company went IPO on 2013-09-25. The firm is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. Evoke is developing its product Gimoti (metoclopramide) nasal spray for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Gimoti, is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a formulation of metoclopramide offering systemic delivery by nasal spray administration.

EVOK Intrinsic Value
HIDDEN
Show
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-36.2%
=
Net Income
-5.2m
/
Revenue
14.4m
What is the Net Margin of Evoke Pharma Inc?

Based on Evoke Pharma Inc's most recent financial statements, the company has Net Margin of -36.2%.

Back to Top